EDITORIAL SECTIONS

Nancy Kapila is a seasoned pharmaceutical consultant with over 5 years of varied experience and a Master’s in Pharmaceutics from Panjab University. She excels in drug mechanisms and interactions. Her career highlights include collaborating with numerous pharmaceutical companies and offering strategic insights and guidance. Nancy stands out for her dedication to keeping abreast of pharmaceutical advancements, regulatory changes, and emerging trends. She believes in continuous learning to navigate the industry’s complexities and provide innovative client solutions. Fascinated by the role of data analytics in decision-making, Nancy delves into data to uncover patterns and opportunities, offering evidence-based recommendations for process optimization, product development, and operational efficiency. Her career is driven by a relentless pursuit of knowledge, passion for data insights, and commitment to leading pharmaceutical companies towards success in a dynamic industry.

Ryan Varghese is a student and researcher affiliated with the Department of Pharmaceutical Chemistry, Poona College of Pharmacy, India. His work spans a spectrum of topics from artificial intelligence to cancer theranostics and drug delivery in Alzheimer's disease.His specialisation lies in the drug delivery modalities in chronic diseases. He has curated several articles on the lacunae in the Government public policies while providing solutions for the same. His recent works include the proposal of drug repurposing and affordable hospitalisation to mitigate the risk stemming from COVID-19 in India.

Sahil Salvi is a student and researcher associated with the Department of Pharmaceutical Chemistry, Poona College of Pharmacy, India. His works spans across a broad variety of topics, with specialisations in drug delivery and pharmaceutics, especially in chronic diseases. His keen interest in the latter has driven him to curate scientific articles in pharmaceutics and pharmacology.

Dileep Kumar is an assistant professor in the Department of Pharmaceutical Chemistry at Poona College of Pharmacy. He is a pioneer in his field with his forte in the treatment and novel drug delivery in Cancer and Alzheimer’s disease, especially adamantyl analogs as GluN2B selective NMDA receptor agonists. He is also an awardee of the Junior Research Fellowship from the National Medicinal Plant Board (NMPB) New Delhi, Senior Research Fellowship from the University Grants Commission (UGC), Teaching Assistantship, and Institute Post-Doctoral Fellowship from IIT (BHU) Varanasi. He is the Guest editor of Prestigious journals like Current Topics in Medicinal Chemistry, CTMC, Current drug target, combinatorial chemistry, and molecules.

Surbhi Gupta is an Industry Principal at Frost & Sullivan with extensive experience in global pharmaceutical and biotech market research and consulting. She leads the Personalized Therapeutics program, focusing on next-generation modalities and precision medicine. Her expertise spans market analytics, forecasting, and competitive benchmarking, supporting strategic decision-making for global clients. Recognised as a trusted growth advisor, helping stakeholders navigate disruption, accelerate innovation, and capture transformative growth opportunities across the evolving biopharma landscape.

Chang supports the preclinical-to-clinical PKPD translation and human efficacious dose prediction of new biological entities at Boehringer Ingelheim. Dr. Chang obtained his MS and Ph.D. in Pharmaceutical Sciences at the University at Buffalo. Under Dr. Dhaval Shah’s mentorship, Dr. Chang investigated antibody and protein therapeutic disposition in the rat brain using large-poremicrodialysis and developed a translational brain PBPK model for monoclonal antibodies.

Dhaval K Shah is an Associate Professor of Pharmaceutical Sciences at the State University of New York at Buffalo. Prior to becoming the faculty Prof. Shah served as a Principle Scientist in the ‘Translational Research-Modeling & Simulation’ group at Pfizer Inc. His research focuses on understanding the determinants for the absorption, distribution, metabolism, and elimination (ADME) of protein therapeutics. His lab uses the principles of Pharmacokinetics-Pharmacodynamics (PK-PD) Modeling & Simulation to support the discovery, clinical translation, and late phase development of novel biologics like engineered antibodies, multi-specific proteins, immuno-oncology agents, engineered T cells, and antibody-drug conjugates.

Shengjia Wu is a PhD student in the pharmaceutical sciences at the State University of New York at Buffalo. His research focuses on understanding and modeling the macromolecule distribution in the central nervous system.

Yingyi Li gained her master’s degree of pharmaceutical sciences in University at Buffalo. When Yingyi was a master student, she was working in Dr. Dhaval Shah’s lab and became more experienced in PBPK modeling. Yingyi is currently a scientist in the field of pharmacometrics and translational PK-PD in Enhanced Pharmacodynamics.

I am Chanchal Kumawat. I started my journey in science as Ph.D. student at Regional Centre for Biotechnology and continued as postdoctoral fellow at Max Perutz labs, Austria.  I enjoyed making scientific discoveries in the laboratory and now, enjoy communicating it as a science writer.